For instance, we observed upregulation of EZH2 in liver cancer samples with a mutation in the predicted distal enhancers of the EZH2 gene, which is known to promote hepatocellular carcinoma (HCC) progression and metastasis (43,44) and its inhibitors are currently being tested in clinical trials (45). This evidence concerns the gene EZH2 and liver cancer.